Teva Pharmaceutical Industries ADR (TEVA)

Jun 5, 2025, 7:09 AM EDT - 16 hours ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Jun 3, 2025, 5:30 PM EDT - 2 days ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Jun 3, 2025, 7:16 AM EDT - 2 days ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

May 30, 2025, 9:05 PM EDT - 6 days ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025, 9:00 PM EDT - 6 days ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 29, 2025, 8:00 AM EDT - 7 days ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 27, 2025, 5:30 PM EDT - 9 days ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025, 4:30 PM EDT - 9 days ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025, 3:44 PM EDT - 9 days ago

Why Is Teva Stock Trading Higher On Tuesday?

May 27, 2025, 8:30 AM EDT - 9 days ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 23, 2025, 12:52 PM EDT - 13 days ago

Why Investors Should Watch Teva Despite Regional Risks

May 22, 2025, 1:56 PM EDT - 14 days ago

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 20, 2025, 5:22 PM EDT - 16 days ago

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025, 4:30 PM EDT - 16 days ago

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 19, 2025, 4:52 AM EDT - 17 days ago

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

May 19, 2025, 4:52 AM EDT - 17 days ago

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

May 15, 2025, 6:12 PM EDT - 21 days ago

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 8, 2025, 11:33 AM EDT - 4 weeks ago

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

May 7, 2025, 1:01 PM EDT - 4 weeks ago

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

May 7, 2025, 12:13 PM EDT - 4 weeks ago

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

May 7, 2025, 11:51 AM EDT - 4 weeks ago

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

May 7, 2025, 10:47 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:30 AM EDT - 4 weeks ago

Teva Pharm first-quarter profit rise tops estimates

May 7, 2025, 7:00 AM EDT - 4 weeks ago

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

May 7, 2025, 7:00 AM EDT - 4 weeks ago

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

May 5, 2025, 11:43 AM EDT - 4 weeks ago

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

May 5, 2025, 7:49 AM EDT - 4 weeks ago

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Apr 9, 2025, 6:32 PM EDT - 2 months ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 9, 2025, 3:59 PM EDT - 2 months ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 7, 2025, 7:30 AM EDT - 2 months ago

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Mar 31, 2025, 1:00 PM EDT - 2 months ago

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

Mar 27, 2025, 4:30 PM EDT - 2 months ago

Teva Releases Q1 2025 Aide Memoire

Mar 27, 2025, 4:30 PM EDT - 2 months ago

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Mar 14, 2025, 6:08 PM EDT - 2 months ago

Drugmakers agree to participate in second round of price negotiations

ABBV AZN GSK MRK NVO

Mar 12, 2025, 12:15 PM EDT - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript)

Mar 11, 2025, 1:07 PM EDT - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 6, 2025, 12:27 PM EST - 3 months ago

Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds

Mar 3, 2025, 4:30 PM EST - 3 months ago

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

Feb 27, 2025, 8:00 AM EST - 3 months ago

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Feb 25, 2025, 4:00 PM EST - 3 months ago

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Feb 24, 2025, 10:48 AM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)

Feb 22, 2025, 2:20 AM EST - 3 months ago

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

Feb 21, 2025, 6:27 PM EST - 3 months ago

Final Trade: TEVA, JNJ, TJX, BABA

JNJ TJX BABA

Feb 21, 2025, 6:44 AM EST - 3 months ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

ALVO JNJ

Feb 18, 2025, 4:30 PM EST - 3 months ago

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Feb 18, 2025, 11:30 AM EST - 3 months ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

ALVO

Feb 18, 2025, 6:00 AM EST - 3 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Feb 17, 2025, 4:42 AM EST - 3 months ago

Teva Pharm CEO calls for faster US generic drug approvals

Feb 11, 2025, 5:20 PM EST - 4 months ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

AXSM

Feb 10, 2025, 12:33 PM EST - 4 months ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

AXSM